Sign up
Pharma Capital

Summit Therapeutics accelerating preparatory activities for next DMD study

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) Richard Pye tells Proactive Investors 2017 was a 'landmark' year for them however a number of critical milestones lie ahead of them.

Top-line results for ezutromid, a potential breakthrough treatment for sufferers of Duchenne Muscular Dystrophy (DMD), a fatal wasting disease that affects boys are expected to be released in Q3.

The read-out from the Phase II proof-of-concept study is expected from September onwards; however, interim data has already revealed a statistically significant reduction in muscle damage and inflammation in patients after just 24-weeks.

 

View full SUMM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.